Most of the side effects of cyclobenzaprine are characterized by sedative and anticholinergic effects, where drowsiness, dry mouth and dizziness are very prevalent. But, the FDA Adverse Event Reporting System (FAERS) has revealed more severe issues through its analysis. In addition to the well-known effects, there are major safety indicators of serious neurological and psychiatric adverse events, such as confusion, hallucinations, and even suicidal behavior (Tu et al., 2025).
The statistics also show the risk of drug abuse, overdose, and overall toxicity. Notably, these adverse events have a median time to onset of about seven days, and close monitoring is necessary, especially within the initial few weeks of therapy. Patients and prescribers should know that the drowsiness is not the only effect that can occur but that the central nervous system effects can be life-threatening.
The cyclobenzaprine drug has a number of critical contraindications and drug interactions that should be observed to provide patient safety. It should also be avoided in patients on monoamine oxidase inhibitors (MAOIs), as the combination will trigger a life-threatening serotonin syndrome. It must also be contraindicated in patients with severe liver impairment, congestive heart failure, or hyperthyroidism history.
When taken concomitantly with other central nervous system (CNS) depressants such as alcohol, benzodiazepines, and opioids, it may cause severe sedation, respiratory depression, and coma (Tu et al., 2025). Moreover, its anticholinergic action can be enhanced with the help of other medications of the same nature, including diphenhydramine. Lastly, CYP1A2 enzyme inhibitors (e.g., fluvoxamine, ciprofloxacin) may increase cyclobenzaprine plasma concentration significantly increasing the risk of toxicity.
Cyclobenzaprine use in pregnancy is an issue of great concern judging by the animal evidence. An experiment conducted on pregnant mice in 2025 showed that there was a high rate of embryo death and severe malformation of morphology including skeletal defects, cleft palate, and brain defects following cyclobenzaprine exposure (Ahmed, 2025).
These results indicate that the drug is teratogenic and embryotoxic, which is probably because of its capacity to penetrate the placental barrier and disrupt normal embryonic development. Hence, there is no need to use it in pregnancy unless it is evidently necessary and has been analyzed in terms of risks and benefits. As far as lactation is concerned, cyclobenzaprine is likely to cause sedation and other consequences in a nursing infant due to its excretion in the breast milk and long half-life. This medication should not be taken during breastfeeding.
Cyclobenzaprine is a medication that is very accessible in terms of cost. The generic formulation is cheap and the average
Take the example of a 45-year-old healthy female who presents herself to the clinic with a chief complaint of severe lower back pain. It started hurting her two days ago when she assisted a friend in carrying heavy furniture. She reports pain to be achy and tight with an 7/10 rating, and reports that she experiences visible muscle spasms in her lower back. Her neurological assessment is normal, with no radiculopathy, including leg weakness, numbness, or missing reflexes.
Her examination is an acute musculoskeletal back strain. The original management strategy contained the recommendations of relative rest, heat to the concerned area, and ibuprofen 600 mg three times per day with food. Nonetheless, she shows up later in a follow-up visit complaining that the ibuprofen has been partially effective in alleviating the painful feeling, but the crippling muscular spasms continue and she is unable to sleep and carry out her activities of daily living.
In order to treat the ongoing muscle spasms, the Nurse Practitioner opts to include cyclobenzaprine 5 mg thrice a day on a temporary seven-day course to the current ibuprofen therapy. This is an evidence-based decision. According to Pourmand et al. (2023), cyclobenzaprine is one of the most commonly prescribed muscle relaxants in the treatment of acute back pain in the emergency department. Moreover, critical review by
The role of the Nurse Practitioner in the cyclobenzaprine therapy is not just limited to the first prescription. It entails the use of the lowest dose of treatment at the shortest time, which is in accordance with evidence-based guidelines. Close observation is necessary with attention to both efficacy, which is the decrease in pain and spasm, and safety, including the evaluation of the effects of sedation, dizziness, and anticholinergics. It is essential to schedule a follow-up in one to two weeks to determine the continued necessity of the medication and to measure any negative outcomes that might have occurred (Oldfield et al., 2024).
The NP should also exercise some level of caution against possible abuse. Importantly, the NP must be a leader in deprescribing, and actively abandon the drug after the acute spasm has settled or if the side effects start to be more significant than the therapeutic effect, thus reducing the risk to the patient.
0
117